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Retinal hemangioblastoma (also referred to as retinal capillary hemangioma) is a benign
lesion originating from the endothelial and glial components of the neurosensory
retina and optic nerve head. Historically known as a manifestation of the von Hippel-
Lindau (VHL) disease, it can be seen as an isolated finding or in association with
some rare ocular conditions. In addition to characteristic ophthalmoscopic features,
results of numerous ancillary tests including angiography, ultrasound, optical coherence
tomography, and genetic tests may support the diagnosis and differentiate it from similar
conditions. Because of serious life-threatening complications of VHL disease, every
ocular approach to retinal hemangioblastomas should be in relationship with additional
multidisciplinary diagnostic and therapeutic efforts. In addition, any patient with actual
or probable diagnosis of VHL disease should be screened for ocular involvement.
Unfavorable visual loss can occur early, and ocular complications of VHL range from
exudative retinopathy to tractional retinal detachment, neovascular glaucoma, and
phthisis bulbi. Accordingly, various treatment methods have been tested with overall
acceptable responses, including photocoagulation, cryotherapy, photodynamic therapy,
plaque radiotherapy, vitrectomy, and more novel intravitreal injections of anti-vascular
endothelial growth factors and propranolol.
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Retinal hemangioblastoma (RH), also known as
retinal capillary hemangioblastoma, is a benign
vascular neoplastic lesion originating in the
neurosensory retina or optic disc. Vigla described
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hemangioblastoma in a patient who died of central
nervous system (CNS) lesions for the first time in
1864.[1] Hemangioblastoma presents as a highly
vascular, and well-bordered, slowly growing neo-
plastic lesion that contains a mixture of stromal
cells, endothelial cells, pericytes, and mast cells.[2]
RHs are usually observed in von Hippel–Lindau
(VHL) disease, which is an autosomal dominantly
inherited condition, in which mutations in the VHL
tumor suppressor gene is believed to cause the
development of characteristic benign and malig-
nant, mainly vascular, neoplasms or cysts in the
CNS and internal organs.
RH is one of the earliest and most frequent
manifestations of VHL disease.[3] Sporadic RH
can also occur in the absence of VHL disease.
According to theWebster et al’s report, the features
of sporadic retinal hemangiomas including age of
presentation, degree of visual morbidity, complica-
tions, morphology, and anatomic location of tumors
are indistinguishable from those seen in the VHL
disease.[4]
The prevalence of VHL was reported as 30–
58% among patients with RHs.[5] In the study by
Niemelä et al including 36 patients with retinal
hemangioblastomas, 11 cases had definite clinical
diagnosis of VHL and ten cases were diagnosed
with clinically suspected VHL.[5] In the same study,
visual prognosis of affected individuals was more
favorable in non-VHL patients than in VHL patients,
which was in contrast with the finding of the study
mentioned earlier.[4] Some reports have disclosed
that RHs exist in association with other retinal
conditions, such as chorioretinal coloboma and
Marshall–Stickler syndrome.[6, 7]
Given the life-threatening nature of some of the
complications and manifestations of VHL, timely
intervention needs appropriate surveillance, and
proper diagnosis can be made based on clinical
criteria and genetic evaluation for mutations in the
VHL gene.
METHOD
We searched PubMed and the Web of Knowledge
databases to extract all published studies about
VHL disease from inception to March 2019. “Von
Hippel-Lindau”, “Retinal capillary hemangioma”,
“Diagnosis”, and “Treatment” were used as the
keywords. We also reviewed the reference lists
of related studies. No language restriction was
applied. Two independent investigators screened
the abstracts and titles of extracted articles to
determine the eligible publications. They reviewed
the full text of the pertinent articles. Discrepancies
were resolved through consensus.
VHL Disease
VHL disease is an exceedingly penetrant, auto-
somal dominantly inherited, multisystem neoplasia
disorder caused by mutations in the VHL gene.
Although VHL is hereditary in the majority of cases,
new mutations are the cause in up to 20% of
the cases.[8] Cardinal manifestations include brain
and spinal cord hemangioblastoma, renal cell car-
cinoma (RCC), RH, pheochromocytoma, epididymal
and broad ligament cystadenomas, endolymphatic
sac tumor, pancreatic neuroendocrine tumors, and
renal and pancreatic cysts.[9] The approximate
incidence of VHL disease is 1 in 36,000 live births,
and the penetrance is over 90% by 65 years of
age.[10] The most reported causes of mortality are
metastasizing RCC and CNS lesions,[11] and despite
advances in clinical management, life expectancy
for VHL patients remains low at 40–52 years.[8]
However, improvements in early diagnosis, surveil-
lance, and treatment have led to better prognoses,
and an expert multispecialty team is necessary for
the optimal management of this complex disease.
History
The first pieces of the VHL syndrome puzzle began
to be recognized in the late 19th century.[12] These
earliest findings of the disease have been summa-
rized by Melmon and Rosen.[13] In 1904, von Hippel
published clinical data describing the features of
a retinal disease in two patients and seven years
later, he had been equipped to perform a histo-
logical examination on a subsequently enucleated
eye of one of his patients; von Hippel named
the pathological findings “angiomatosis retinae.” In
1926, the Swedish pathologist Lindau revealed the
relationship between retinal and cerebellar heman-
gioblastomas and their association with cysts in
some viscera including the kidney, epididymis, and
pancreas as components of a hereditary syndrome.
Accordingly, a CNS hemangioblastoma was known
as a “Lindau tumor”, while the identical retinal
lesion came to be known as a “von Hippel tumor”.
By the time Melmon and Rosen published their
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review, the name of the familial syndrome was
“Lindau disease”. This term was changed to “von-
Hippel Lindau (VHL)” disease in the 1970s. Melmon
and Rosen published the initial clinical diagnostic
criteria for VHL disease in a landmark paper in
1964.[13] Seizinger and colleagues explained the
linkage of the VHL gene to chromosome 3 in
1988,[14] and shortly thereafter, in 1993, Latif and
colleagues discovered the VHL tumor suppressor
gene.[15]
Mechanism of Cellular Dysfunction
VHL disease is caused by some mutations in a
tumor suppressor gene, the VHL gene, present
on chromosome 3 (3p25-26).[15] The product of
the gene is the VHL protein (pVHL), which has
been found to participate in cellular oxygen sens-
ing. Understanding of mechanisms related to the
VHL gene has provided insight into cell signal-
ing and function under normoxic and hypoxic
conditions.[16] VHL gene contains three exons
that produce two distinct spliced mRNAs. The
mRNAs differ in the presence or absence of exon
number 2, known as Isoform I and II, respec-
tively. Although it has been believed that the
second isoform does not produce any endoge-
nous tumor suppressor protein and the Isoform
I is the only form that results in functional pro-
tein, expression of the uncharacterized protein
isoform pVHL172, which is translated from Iso-
mer II, is shown to upregulate a subset of pro-
tumorigenic genes including TGFB1, MMP1, and
MMP13.[17] Following ubiquitous expression of VHL,
Isoform 1 encodes two isoforms of pVHL, which
comprises 213 amino acids and 160 amino acids,
respectively, and both of these isoforms have
tumor suppressor activity.[18] pVHL, which is a part
of the ubiquitin ligase complex and serves as
the substrate-recognition subunit, assigns proteins
for proteasomal degradation. Hypoxia-inducible
factor 1𝛼 (HIF-1𝛼) and hypoxia-inducible factor-2𝛼
(HIF-2𝛼) are among the targets of this ubiquitin
ligase, which undergo prolyl-hydroxylation under
normoxic conditions, authorizing for binding to
pVHL and activation of ubiquitin peptides that
result in proteasomal degradation of HIFs.[19, 20]
It is clear that in the absence of normal pVHL,
HIF-1𝛼 and HIF-2𝛼 are not degraded, but form
heterodimers with hypoxia-inducible factor 1𝛽 (HIF-
1𝛽), and produce transcription factors for a wide
array of over 800 genes.[16] Upregulation of cell
survival proteins by HIF signaling, such as epi-
dermal growth factor receptor and transform-
ing growth factor alpha, in addition to angio-
genesis factors, for instance vascular endothelial
growth factor (VEGF) and platelet-derived growth
factor (PDGF), are hypothesized to play a key
role in the development of neoplastic vascular
lesions in VHL disease, including RH.[21–25] The
significance of other actions of pVHL indepen-
dent of HIF signaling is unclear in VHL disease
pathogenesis.[16]
VHL disease is mostly received from a mutant
copy of the VHL gene from an affected parent and
a normal copy from the other parent. Knudson’s
two-hit model for tumorigenesis indicated that the
somatic inactivation of the normal allele in one or
more cells, in combination with a germlinemutation
in the other allele, causes the mutation to clinically
manifest.[26] In a large study on 181 kindreds with
VHL disease, 42 cases (23%) did not have any
relevant family history, indicating a putative first-
generation diagnosis.[27] In these cases, mosaicism
may explain the underlying germline transmission
from the unaffected parent. Additionally, it can
explain occasional cases in which VHL disease
manifests clinically but initial genetic testing is
negative for mutation.[28] Stolle and colleagues
published a report in 1998 on different genetic
testing methods that helped in the identification of
germline mutations in 100% of families with VHL
disease, establishing the importance of VHL gene
testing for the diagnosis of this condition.[29]
Mutations of VHL are highly varied, ranging from
the base pair substitution in a single amino acid
codon to the complete deletion of the gene.[30, 31]
Many of these mutations target pVHL regulation
of HIF signaling. However, the heterogeneous
manifestations of VHL disease suggest that differ-
ent mutations may affect pVHL-associated cellular
mechanisms in different ways.[32] The relationship
between the type of VHL mutation and the severity
and prevalence of ocular complications has been
investigated in several studies with contradictory
results.[33] Initial findings denied any association
between the type of VHL mutation and visual
function.[34] However, it is now believed that partial
deletion, missense, and nonsense mutations are
correlated with higher prevalence of RHs and
worse visual prognosis, unlike complete deletion
of the VHL gene.[35, 36] Additionally, the location
of a missense mutation in VHL correlates with the
phenotype of ocular VHL disease, and mutations
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in the alpha(a)-domain are associated with a higher
rate of retinal and optic nerve hemangioblastomas
than those in the beta(b)-domain.[37] Different VHL
gene mutations in four VHL families support the
genotype–phenotype correlations.[33]
Diagnosis
Retinal and CNS hemangioblastomas are two main
clinical features of VHL disease and the other
systemic abnormalities have less diagnostic signif-
icance. However, variability in systemic abnormal-
ities is an important feature of this disease. Only
one systemic involvement manifests in some cases
and not all abnormalities present together in many
individuals. The diagnosis can be made when
there are two hemangioblastomas, or one of them
in combination with a visceral manifestation. It is
notable that a positive family history is as valuable
as a CNS tumor in the diagnosis; one index tumor,
such as hemangioblastoma, RCC, or pheochromo-
cytoma, in association with a positive family history
is sufficient to diagnose VHL disease.[38] Genetic
testing is useful in challenging cases for screening
of at-risk family members of a patient with VHL
disease with no family history or visceral lesions.
Screening and Surveillance
Different guidelines have been published for
screening of VHL disease. Among these guide-
lines, the ones designed by Choyke et al have
suggested urinary catecholamine testing, ophthal-
moscopy, brain magnetic resonance imaging, and
abdominal computed tomography or ultrasound
for early detection of the manifestations.[39] In the
screening guideline, ophthalmoscopy is recom-
mended to begin from infancy and to be repeated
yearly.
As VHL disease is complex, optimal manage-
ment involves care by a multispecialty team with
expertise in ophthalmology, otolaryngology, neu-
rosurgery, endocrine surgical oncology, neuroradi-
ology, urology, pathology, genetics, and rehabilita-
tion medicine.
Ocular Manifestation of VHL Disease
Although RH is one of the most common clinical
manifestations of VHL disease, the precise preva-
lence of ocular involvement is difficult to ascertain
from case series. Singh et al reported that retinal
capillary hemangioma is the most frequent and
the earliest manifestation of VHL disease. The
frequency of occurrence has been reported to
vary from 49% to 85%.[40] In another article, it is
claimed that RHs are seen in as many as 60% of the
patients, being the second most frequent manifes-
tation after CNS hemangioblastomas.[8] Whether
the most frequent or not, RHs are often the
first manifestation. Although retinal lesions are
hamartomas in nature, they are usually not present
at birth.[41] The mean and median age of onset
is 25 and 21, respectively, which is the lowest
among the other clinical features.[9, 42] RH often
manifests as a solitary lesion. However, around
one-third of patients may have multiple retinal
hemangiomas and up to half of the patients
may present with bilateral involvement.[40] It has
been shown that there is no effect of gen-
der on the laterality and severity of the ocular
involvement.[43]
In a large cross-sectional study in which partici-
pants were identified based on a diagnosis of VHL
disease independent of ophthalmologic features,
335 of 890 patients from 220 unrelated pedigrees
were found to have ocular involvement.[42] Of those
with ocular disease, 42% had unilateral involve-
ment and 58% had bilateral involvement. Affected
patients were from 7 to 84 years old (mean –
36 years old), and 45% were male. In the study,
RHs of VHL were found in all ages and racial
groups, and in both sexes. Results of the study
confirmed the findings of one previous study about
the lack of effect of sex on the ocular phenotype
of VHL patients. Among the main demographic
features considered in the study, only age was
found to have an effect on ocular phenotype,
and only in some respects. However, the authors
did not find a significant correlation between
increasing age and either the laterality, number
of RHs per eye, or the extent of peripheral retina
angiomatosis. This suggests that the probability
for the formation of new lesions in the eye may
not remain constant over time. Webster et al[43]
also did not find an age correlation to number of
tumors. Dollfus et al[44] reported increases in RH
number from the start to the end of their study, but
a statistical relationship with age per se was not
evaluated.
The ophthalmoscopic findings of VHL disease
are divided into two main groups: angiomatous
versus non-angiomatous lesions.
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Angiomatous Tumors or Retinal Capillary
Hemangiomas
Similar to other retinal lesions, retinal capillary
hemangiomas are characterized by location, type,
and size of the tumor. These tumors can be
classified on the basis of morphology (endophytic,
exophytic, and sessile), location within the retina
(peripheral and juxtapapillary), and effects on the
retina (exudative form and tractional form).[40] The
retinal capillary hemangioma is usually a well-
circumscribed, round bulging with a red to orange
color, with a variable appearance depending upon
whether the tumor is endophytic, sessile, or exo-
phytic. Blood vessels, as draining and feeding
vessels, appear as the tumor grows larger and
begins to be increasingly enlarged and tortuous
[Figure 1(A)]. At this stage, extrapapillary RHs
become exudative, with hard exudates and retinal
edema near the tumor and/or in the macula. RHs
at or near the optic disc have a distinct clinical
appearance, making them difficult to discern with
ophthalmoscopy when small in size or sessile in
form. A localized fullness of the disc margin may
be the primary finding, but with further growth,
a bordered pink thickening becomes visible, with
associated fine vessels in some cases. Feeder and
draining vessels are typically not visible in juxta-
papillary lesions. Although papillary hemangiomas
sometimes show minimal growth over years, they
usually lead to exudation eventually.
In a study by Wong et al it was reported that 85%
of the affected eyes, manifested RHs exclusively
in the peripheral retina (extrapapillary), 8% had
RHs exclusively near the optic disc, and 7% had
RHs in both the peripheral retina and juxtapapillary
regions. Among the 421 eyes with peripheral RHs,
themean tumor count was 2.5. A subtle red or gray-
ish spot with a few hundred micrometers of diam-
eter was the initial clinical appearance of an extra-
papillary RH, with an ophthalmoscopic appearance
mimicking a dilated capillary, microaneurysm, or
small intraretinal hemorrhage. Small tumors were
sessile, but with growth, they often became more
nodular. Earlier, Singh et al[41] reported 174 retinal
capillary hemangiomas in 86 eyes of 68 patients
with VHL disease, where 83% were extrapapillary
and 17% were juxtapapillary; 58% of RHs were
1.5 mm or smaller in size. In addition to data
from distribution of RHs, the authors reported that
juxtapapillary hemangiomas are frequently located
at the temporal border of the optic disc.[40, 41]
The natural course of a single capillary heman-
gioma in the retina can be of progression, stability,
or regression. A majority of RHs grow over time,
but occasionally, untreated tumors may remain
static for a long period, and rarely they may
regress spontaneously.[45] Secondary effects such
as exudation of subretinal or intraretinal spaces are
often limited to the territory of the hemangioma
but can be far enough to produce a macular star
exudate. Retinal or vitreous hemorrhages are rarely
observed, occurring in less than 3% of cases.[46]
Without treatment, large or multiple adjacent RHs
may grow to displace the retinal structures and
cause an exudative retinal detachment.
Fibrosis of the epiretinal space followed by
posterior hyaloid contractionmay accompany large
RHs, causing macular epiretinal membrane with
macular thickening, vitreomacular traction, or trac-
tion retinal detachment. As a rare complication,
neovascularization of the iris can occur, which may
lead to the development of neovascular glaucoma
(NVG) and phthisis bulbi in eyes with multiple
tumors. In a study involving a large cohort of
patients, only 2% of eyes had neovascularization of
the iris.[43] Eventually, such eyes became phthisical
or painful, requiring enucleation.
Visual function of patients with retinal capillary
hemangiomas has been evaluated in some studies.
Chew, in her prospective case series,[35] reported
that in 406 patients with VHL disease who had
ocular involvement, visual acuity was 20/20 or
better in 84.5% with hemangioblastomas, 3% were
legally blind, and eventually, 8.2% had unilateral
enucleations. In the cohort of the National Eye
Institute, about 77% of eyes had a vision of 20/20
or better, and the prevalence of legal blindness,
that is, vision less than 20/160 in the better-seeing
eye, was 6%. However, to justify the burden of the
disease, it was reported that approximately 20% of
all patients with ocular VHL disease had at least
some degree of unilateral visual impairment.
A longitudinal analysis with the purpose of
characterization of visual function and ocular VHL
progression was conducted in 2012.[47] Two hun-
dred and forty-nine participants of the study were
followed-up for more than two years. Visual acuity,
ocular manifestation of VHL disease, germline
mutation in the VHL gene, demographic data,
and patient characteristics were recorded in that
study. The anatomic and functional ocular status
was stable in most of the patients over a mean
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Figure 1. (A) Color fundus photograph of an exudative extrapapillary RCH. Note enlarged and tortuous feeding vessels passing
toward a peripheral RCH, in addition to small RCHs in macula. (B) Wide field fundus angiogram. (C) Montage modality of
angiography for more peripheral lesions.
follow-up period of 8.2 years. In addition, 88%
of eyes with ocular VHL disease at baseline, did
not demonstrate RHs in a new retinal location,
70% remained stable in terms of RH number, and
79% revealed no change regarding the extent of
RH involvement. In all 498 studied eyes, visual
acuity was decreased by 5.1 letters across follow-
up, with 16.1% decreasing by more than 10 let-
ters.
In affected eyes, greater vision loss was related
to the increase in RH number, the presence of
juxtapapillary RHs, and formation of new RHs.
There were correlations between younger age
at onset of ocular VHL disease, bilateral ocular
VHL disease, and missense or protein-truncating
germline mutations and increase of anatomic
involvement and functional worsening. Various
stages of retinal involvement in retinal heman-
giomas have been determined by some authors.
Sigelman classified them into five stages. Stage
one represents small hemangioma without any
feeder vessels. In stage two, they appear as a
nodule with prominence of only the draining vein.
In stage three, both feeding artery and draining
vein are present with or without retinal exudates.
Partial and total exudative retinal detachment are
observed in stages four and five, respectively.[48]
Similarly, Vail’s classification[49] includes the follow-
ing stages:
Stage I: Angioma formation with feeding artery
and draining vein
Stage II: Development of hemorrhages and exu-
dation
Stage III: Massive exudation and retinal detach-
ment
Stage IV: Uveitis, absolute glaucoma, and loss of
the eye
The ophthalmoscopic findings of RHs are
characteristic; thus, a good funduscopic
examination is often sufficient to make an
ocular VHL disease diagnosis. As mentioned
earlier, small lesions may be difficult to be
distinguished from microvascular abnormalities
when other conditions are considered. On
the other hand, some lesions may closely
resemble larger RHs and may be difficult to be
differentiated in some cases. Vasoproliferative
tumor of the ocular fundus is the main
differential diagnosis of large RHs.[50] In
addition, RHs in the presence of macular
exudation can be misdiagnosed as retinal
macroaneurysm or Coats’ disease, and in
some conditions such as vitreous hemorrhage
which masks the tumor, dilated feeder vessels
can be misdiagnosed as congenital retinal
arteriovenous malformations and anastomoses
between vessels of choroidal melanoma or
retinoblastoma and retinal vessels. Unilateral
papilledema and papillitis, juxtapapillary
choroiditis, choroidal hemangioma, choroidal
neovascularization, and amelanotic choroidal
melanoma can mimic juxtapapillary retinal capillary
hemangioma.[51]
Non-angiomatous Findings in Ocular VHL
Disease
Some non-angiomatous retinal lesions associated
with ocular VHL disease have been described.
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These lesions include “twin vessels,” “vascu-
lar hamartomas,” and “vascularized glial veils.”
Schmidt, in 1995, found some unusual retinal
lesions in his cases and called them vascular
hamartomas.[52] The lesions were described as
small, flat, moss fiber-like, vascular lesions with-
out enlarged afferent and efferent vessels. They
were located in the superficial retina. Juxtapap-
illary fibrovascular membranes termed vascular-
ized glial veils had been introduced by the same
author seven years earlier. In the same year,
de Jong et al defined twin vessels as a paired
retinal arteriole and venule that were separated
by less than the diameter of one venule and that
extended for a distance of more than one disc
diameter.[53]
In 2008, Wai et al reported a form of vascu-
lar proliferation as fine superficial vessels in 16
eyes of 14 patients, often found in juxtapapillary
locations.[54] These lesions most closely resem-
bled vascularized glial veils. So that, the authors
preferred the term “retinal vascular proliferation”
to “vascularized glial veils” to include lesions that
do not have a prominent fibrovascular component.
Although the lesion was stable in 7 of 13 eyes, in
the remaining cases, the lesion was so progressed
that it led to vision loss.
Ancillary Tests
Fundus photography with wide-field modalities
and montage methods seems to be an effective
technique to monitor progression and growth of
retinal hemangiomas, in addition to its use in
detecting medium to large lesions [Figures 1(B)
and 1(C)]. Ancillary testing becomes crucial in the
evaluation of those patients with smaller lesions
and those with peripheral exophytic hemangiomas
to confirm the diagnosis. Ancillary tests for retinal
hemangiomas may include fluorescein angiogra-
phy (FA), indocyanine green angiography (ICG),
optical coherence tomography (OCT), and ultra-
sonography.
Vascular dye tests such as FA and ICG angiog-
raphy are advantageous diagnostic tools used
in a range of ocular vascular growths such as
retinal capillary hemangiomas, where FA is known
as the most useful diagnostic tool because of
the vascular nature of the tumor.[55] FA and ICG
angiography are critical in the assessment of any
vascular lesion, helping in outlining the distinctive
appearance, in addition to confirming any associ-
ated leakage.[56]
Fluorescein Angiography
Primary hyperfluorescence of the feeder artery
during the arterial phase associated with fine
capillary filling of the retinal lump and cumulative
hyperfluorescence within the entire tumor during
later phases is the main finding of retinal angiog-
raphy in RHs.[57] In more exophytic forms, FA may
help clinicians to delineate the lesion, as well as the
demarcation of the tortuous arterioles and venules.
In circumstances that necessitate treatment, angio-
graphic studies are also supportive in differenti-
ating draining venules from feeding arterioles.[58]
In juxtapapillary hemangioblastoma, fine vascular
configuration can be revealed on angiograms.
Wide-angle angiography may be more beneficial,
especially in finding peripheral lesions, which are
more vulnerable to be missed because of their
outlying position and subtle presentation. Although
it is helpful in diagnosis, handling, and assessing
the therapy, it is not required to perform FA on all
cases of characteristic capillary hemangioma.
Indocyanine Green Angiography
ICG may also be valuable in the assessment
of RH, although, generally, it is used to assess
choroidal vasculature. Filling of the angiomas
creates early, demarcated hyperfluorescence on
ICG that is in communication with retinal vascu-
lature. Absence of choroidal contribution on ICG
angiography supports the diagnosis of RH. ICG
is useful in distinguishing clinically similar situa-
tions, such as focalized choroidal hemangioma,
which would be limited to the choroidal level.[40]
Associated retinal hemorrhages or retinal vascular
leakage may be discovered by the blockage of
adjacent vasculature on ICG, as an adjunct to
FA. Indocyanine green-mediated photothrombo-
sis has also been reported for the treatment of
RHs.[59]
Ultrasonography
Ultrasound is a critical modality in assessing
intraocular tumors. Evaluating size, diameter, and
internal echogenicity, B-scan remains an important
test in approach to ocular tumors. In RHs, B-scan
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shows a well-demarcated retinal lesion without
choroidal properties. Ultrasonography is predomi-
nantly helpful in the presence of opaque media.[60]
Moreover, an RH is characterized on A-scan by
an opening spike with secondary high internal
reflectivity.[40]
Other Diagnostic Tests
Sequence investigation of the VHL gene, can be
important in the evaluation of RHs, as these assist
in the diagnosis of VHL disease. OCT may be
used to discover macular edema and epiretinal
membranes, as well as to evaluate features of a
juxtapapillary RH.
Structural and Molecular Pathology Findings
RHs have two main components: glial prolifera-
tion and endothelial or vascular proliferation. The
primary event is controversial. In fact, it is not
determined whether the primary glial proliferation
causes secondary vascular proliferation or glial
proliferation follows endothelial proliferation.
Primary findings were of those studies con-
ducted nearly half a century ago.[61, 62] It was
shown that proliferation of glial cells surrounded
the proliferated endothelial cells, which were
arranged in well-formed vessels or small nests.
The most prominent feature was a collection of
large capillary-sized blood vessels that substi-
tuted the full thickness sensory retina. In addi-
tion, primary ultrastructural studies indicated that
both endothelial and perithelial elements of the
large capillary unit were morphologically reg-
ular. Thus, capillary hemangioma was a more
exact histopathologic description for the von Hip-
pel angioma than hemangioblastoma or heman-
gioendothelioma. This structure was reinforced
in a study with the purpose of immunohisto-
logical evaluation of RH in two cases, where
the authors reported that ultrastructural find-
ings in both eyes contained endothelial/pericyte-
lined vascular networks, shortened stromal cells,
and fat and vacuolated stromal cells with ultra-
structural features consistent with glial cells.[63]
Pathological findings of extrapapillary heman-
giomas treated with xenon photocoagulation,
argon laser therapy, and cryotherapy showed
occlusion of the vascular channels, fibrous meta-
plasia of the retinal pigment epithelium, and sec-
ondary gliosis.[64]
Chan et al in 2007 tried to summarize discover-
ies in VHL pathology.[65] They concluded that loss
of heterozygosity (LOH) within the VHL gene is
noticed in the stromal cells which originate from
vascular/endothelial ancestry and form a unit with
glial cells in retinal hemangiomas. Parallel LOH
has been established in VHL disease-related CNS
hemangioblastomas, which are histopathologically
analogous to RH. This finding is not compatible
with the old belief about stromal cells, where they
were supposed to be lipidized astrocytes or glial
cells.
Chan et al have suggested that increase of
hypoxia-inducible factor (HIF), VEGF, and ubiquitin
are found in ocular hemangioblastomas. In their
study, tumorlet cells were introduced as small,
poorly differentiated cells with dense nuclei and
minor cytoplasm, owning several stem cell and
immunologic markers such as CD133 65. Later in
2015, they found their pathological results to be
consistent with previously described structure for
RHs.[66]
Themainstream of evidence supports the under-
standing that retinal hemangioma is a vascu-
lar growth arising as a malformed vascular unit
containing an arteriole, capillaries, and venule
with consequent growing of all its components.
Endothelial lineage of stromal cells and peripher-
ally located glial cells indicates endothelial growth
as the primary event. More discoveries about the
molecular happenings in RH corpus may provide a
therapeutic target for retinal hemangiomas.
Ocular VHL Disease and Pregnancy
In 2009, Hayden et al published a report of
spinal hemangioma worsening in a pregnant VHL
patient.[67] They believed that hormonal alter-
ations during gestation hastened the growth of
hemangioblastomas, leading to new symptoms.
Following the report, Frantzen et al in their ret-
rospective study involving 29 patients[68] claimed
that pregnancy causes progression of cerebellar
hemangioblastomas. However, in 2015, Binderup
et al criticized the two previous studies for their
retrospective nature, short follow-up period, and
limited samples.[69] Their cohort study exclusively
compared hemangioblastoma risk in pregnancy
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with age-matched non-pregnant years in the same
female group and evaluated the influence of
pregnancy on both CNS and RH progression. In
contrast to the initial impression, they reported that
gestation was associated with even lower rates
of new tumor formation compared with the non-
pregnancy period. It seems that pregnancy does
not have any effect on the growth of preexisting
RHs or development of new lesions.[69]
Treatment of Ocular VHL Disease
Early diagnosis, making decision for treatment
versus observation monitoring for further growth
after primary treatment, management of secondary
retinal complications and treatment complications
are some of the challenges in the field of ocu-
lar VHL disease management. The main goal of
therapy is destruction of the lesion in order to
reduce secondary damage to the retina. Appar-
ently, small tumors in the early phases of growth
can be destroyed quite readily with minimal risk
associated with the treatment. In contrast, as
hemangioblastomas grow, it will be more difficult to
ablate them, with higher risk of damage induced by
the therapeutic procedures. Accordingly, it seems
that the principal issue in the management of
ocular VHL disease is identification of RHs in the
early stages of development, as well as timely
therapy. However, even effectively managed, RHs
can cause life-long visual loss in up to 25% of
cases.[46]
In order to achieve suitable management of
RHs, an optimal approach should be initiated
with adequate surveillance. Indirect ophthalmo-
scopic and biomicroscopic examination of the
retina, with occasional usage of ancillary tests
are indicated every year for individuals with VHL
disease, beginning in early childhood. Documen-
tation of any ocular lesions allows the clinician
to select one of the treatment modalities, includ-
ing observation,[70] laser photocoagulation,[71–74]
cryotherapy,[75–78] plaque radiotherapy,[79] vitre-
oretinal surgery,[80, 81] external beam radiation,
proton beam radiation, photodynamic therapy
(PDT),[82, 83] trans-pupillary thermotherapy, intraoc-
ular injection of anti-VEGF drugs or triamcinolone
acetonide (TA).
Relative regression signs in a small RH may
be detected with close surveillance. In a study
by Singh et al in 2002,[41] regarding management
techniques in 68 patients who had been treated
between 1974 and 1999, 82% of the 77 RHs that
were primarily observed persisted stable for a
median follow-up of 7 years. Most of the RHs that
were initially observed were 3.0 mm or smaller
in size and almost the same percentage of juxta-
papillary and extrapapillary RH were present. The
authors reported that for the extrapapillary RH,
efficiency of observation as a way of management
was higher for hemangiomas that were 1.5 mm or
less in size than for larger RH. In their opinion,
cautious observation is indicated in a reliable
case if the RH is very small (up to 500 𝜇m), is
not associated with exudation, and is not vision
threatening because of a nasal locality.
Ablative Treatment of Extrapapillary RHs
Ablative treatment includes various modalities
such as thermal laser photocoagulation, cryother-
apy, radiation (including brachytherapy, external
beam radiation, and proton beam radiation), PDT,
and trans-pupillary thermotherapy.
Laser Photocoagulation
Laser photocoagulation may be applied in numer-
ous sessions and is most effective in lesions
that are 1.5 mm or smaller,[41] but it also has
been used for RHs up to 4.5 mm with real
regression.[72] Although the modality is classi-
cally used for peripheral tumors, the effective-
ness of laser photocoagulation for juxtapapillary
RHs has been presented in some studies. Per-
manent scotoma, poor visual outcome due to
juxtaposition to optic nerve and posterior position
are possible complications of laser photocoagu-
lation for optic nerve hemangiomas.[70] Various
laser types, including argon, yellow dye, diode,
green, and krypton, have all been used.[41] Effi-
cacy of all kinds of laser photocoagulation has
been confirmed in several studies. For exam-
ple, in Singh’s study, argon/diode laser photoco-
agulation, applied over a mean of 1.2 sessions
was 100% effective in treating retinal heman-
giomas that were smaller than 1.5 mm. Vas-
cular lesions such as RHs can absorb yellow
laser more than other laser wavelengths based
on the absorption range of oxyhemoglobin;[84]
therefore, green and yellow wavelengths are
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usually used, with longer burn intervals (0.2–
0.4 seconds) than would be usual for panreti-
nal photocoagulation or laser retinopexy, and
with power adequate to generate whitening in
the zone of the burn. No randomized trial for
ablative laser type or technique has been per-
formed.
There are different types of photocoagulation
techniques including direct photocoagulation of
the RH,[64, 70, 71] treatment of the feeder vessel,[73]
or combination of both the routes. Because
of the possibility of bleeding caused by laser
treatment, in some studies, blood vessel pho-
tocoagulation has been recommended to dimin-
ish blood flow of the retinal lumps.[85] Blodi’s
study[73] revealed that both direct and feeder
vessel photocoagulation procedures are effec-
tive, but laser photocoagulation of the feeder
arterioles may cause the need for further laser
sessions. In cases with small tumors, burns are
generally restricted to an area appropriate to
blanch the entire lesion surface; feeder vessels
in these tumors are so small, if detectable at
all. An effective laser photocoagulation yields a
chorioretinal scar, which is occasionally associ-
ated with a wasted, pale pink remnant of the
lesion, and other times with complete vanishing
of the RH. A visible regressed lesion may be a
sign of destruction sufficient to prevent further
growth or exudation, but cured areas must be
followed over time for any signal of a still viable
RH. If required, retreatment technique will be the
same. In larger tumors, it will be challenging to
apply intense photocoagulation throughout the
depth of the tumor. Long duration burns (often
more than 0.4 sec) with a lower power setting
may be involved in the treatment of masses
with a size between 1.5 and 4.0 mm in order
to cause progressive whitening over the path of
the burn. Although the visibility of the feeder
vessels is enhanced in large tumors, photoco-
agulation of the feeding arterioles has not con-
siderably increased the probabilities of success
or lowered the risks associated with the proce-
dure.
Occasionally, indirect laser photocoagulation is
applied for tumors that are present anterior to the
equator, where slit lamp laser delivery may be
difficult. In addition, reasonable accomplishment
rates have been reported with the use of laser
endophotocoagulation as an adjunct to vitreoreti-
nal surgery[86].
Following laser therapy of both small and large
tumors, appearance of scarce intraretinal or prereti-
nal hemorrhage on the treated tumor is common,
but vitreous hemorrhage is rare. Other reported
complications of laser photocoagulation are sub-
retinal fluid accumulation and exudative retinal
detachment.[87]
It is notable that for laser therapy, sessile masses
are more suitable than very nodular ones, and
exudation, preexisting hemorrhage, and epiretinal
fibrosis may have a negative effect on proper laser
treatment. In addition, practicability and usefulness
of therapy depends on a number of issues such
as tumor location, grade of exudation, presence of
retinal detachment, associated chorioretinal scar-
ring, location relative to the position of any previous
scleral buckling, the number and appearance of
other viable tumors, concomitant retinal vascular
alterations or vascular proliferation, and reaction to
prior treatment(s).
McCabe et al reported a large series of patients
that had been treated with laser photocoagula-
tion with variable functional results. They con-
cluded that due to the absence of standard-
ization of laser photocoagulation, the functional
consequences were not comparable.[88] Huang
et al reported the individual tumoral response
in a total of 39 retinal capillary hemangiomas
using a 532-nm laser system[87]. RHs < 1 optic
disc diameter were directly photocoagulated. For
RHs > 1 disc diameter, the nourishing ves-
sel was photocoagulated first, followed by mul-
tiple tumor bulk photocoagulations until tumor
atrophy occurred. Of all tumor bodies treated
with photocoagulation, 82.4% were controlled at
the last visit. The percentage of tumors treated
with photocoagulation was 76.5%, which was
similar to the rate (74%) reported by Singh
et al.[41, 87]
Cryotherapy
Although there are few reports about the efficiency
of laser photocoagulation for huge RHs, according
to the experience of the authors of this review, a
substantial number of RHs in this size range are
not destroyed even following several sessions of
laser photocoagulation. Along with laser therapy,
trans-scleral cryotherapy can be effective for the
destruction of these masses, even in the pres-
ence of simultaneous exudation, hemorrhage, or
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fibrosis. Similarly, Singh et al reported that accom-
panied with laser photocoagulation, cryotherapy is
the backbone of treatment for RHs > 1.5 mm in
diameter and are placed anteriorly with subretinal
fluid.[41] For more anterior tumors, cryotherapy
may be applied trans-conjunctivally in the office
setting, while for posteriorly located tumors, a
conjunctival incision may be needed to provide
proper placement of the cryo probe. Numerous
studies have shown cryotherapy effectiveness,
particularly when RHs < 3.75 mm.[64, 71, 76–78] As
described byWelch, cryotherapy should be applied
till the ice ball completely encloses the RH.[72]
Double freeze–thaw technique is usually used
for cryotherapy. Use of cryotherapy seems to be
associated with a more post-treatment exudative
response than the use of laser photocoagula-
tion.
Radiotherapy
External beam radiotherapy, proton beam
radiotherapy,[89] and plaque radiotherapy[79] are
additional modalities for large tumors (> 4.0 mm
in diameter), which demonstrate poor response to
cryotherapy and laser photocoagulation.
Although commonly used in the management
of choroidal hemangioma, brachytherapy was not
used for the treatment of RH until 1998.[90] Kreusel
and colleagues reported the use of ruthenium-
106 brachytherapy for treatment of 25 eyes.[79]
The mean width of treated hemangiomas was
3.8 mm, the mean apex dose was 126 ± 36
Gy, and the mean scleral contact dose was
518 ± 85 Gy. Dose was transported over five
to seven days. Finally, the authors reported
destruction of 23 out of 25 masses with a
single radiotherapy session. Nine eyes showed
post-radiation complication including severe visual
acuity reduction, a persisting exudative retinal
detachment, or a recurrent traction detachment.
Risk factors for these complications included
pre-treatment exudative retinal detachment and
tumor size > 3.75 mm. It is recommended to
restrict the use of brachytherapy to moderately
sized RHs < 3.75 mm without exudative reti-
nal detachment. In Singh’s series, a total of
four extrapapillary RHs with a mean size of 4.5
mm (3–6 mm) were treated with iodine 125
plaque, delivering an average apical dose of 34.8
Gy.[41]
For the first time, Palmer and Gragoudas suc-
cessfully treated one patient with a juxtapapillary
hemangioma with proton beam therapy.[89] Sixteen
years later, the report of Seibel et al in 2014,
described the treatment of a series of eight patients
with symptomatic retinal papillary capillary heman-
gioma with proton beam therapy.[91] This series
of progressive stages of papillary hemangioma
demonstrated an acceptable anatomic outcome
after proton beam therapy. However, poor early
visual acuity attributable to central exudation and
long persisting macular edema compromised the
final visual outcome. The authors advise that even
in those patients ineffectively treated with laser
photocoagulation or PDT, exudation may entirely
resolve when proton beam therapy is used as
a secondary treatment. Although proton beam
therapy is a therapeutic option in the treatment
of retinal papillary hemangioma, according to
these findings, the treatment will remain challeng-
ing.
Not widely used, application of external beam
radiation has been pronounced in advanced cases
without favorable long-term consequence.[92]
Transpupillary Thermotherapy
Transpupillary thermotherapy (TTT) has an uncer-
tain role in the treatment of RHs. There are lim-
ited experiences in the treatment of VHL with
this modality. Parmar in 2000 and Singh in
2002 reported treatment of juxtapapillary RHs
with trans-pupillary thermotherapy in one and
three patients, respectively.[93] In the first case,
TTT caused an improvement in visual acuity
from counting fingers to 6/24 and an obvi-
ous decline in exudates surrounding the heman-
gioma. However, in three patients in the sec-
ond study, there was no apparent effect in
two cases, although, in the third patient, it
caused whole fibrosis of the juxtapapillary heman-
gioma associated with concomitant optic atro-
phy.
Photodynamic Therapy (PDT)
PDT is increasingly used for the treatment of
RH, mainly for large tumors or juxtapapillary
hemangiomas. Studies using verteporfin PDT
for both juxtapapillary and peripheral RH have
revealed diverse anatomical and functional
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conclusions.[94] Schmidt-Erfurth et al, in a
prospective non-comparative case series,
reported that PDT is effective in reducing tumor
dimension and exudative activity of optic disc
head hemangiomas.[82] A study reported the effect
of PDT on four eyes with juxtapapillary RH. Two
eyes was treated by full PDF while two other
eyes was treated by half PDT. Tumor regression
was observed in two eyes while no change
was remarked in tumor size in other eyes.[94]
The study showed that PDT can be effective in
decreasing macular edema associated with RH,
but this does not constantly correspond with
an enhancement of visual acuity, particularly for
juxtapapillary tumors. In a retrospective analysis
of all patients with RH treated with PDT between
2003 and 2010,[95] it was concluded that the
response of RHs to PDT is unpredictable; however,
PDT may be used in juxtapapillary tumors where
radiotherapy or cryotherapy is expected to result
in simultaneous visual loss. Recently, in Huang’s
study,[87] it was shown that good long-term vision
outcomes were acquired in some peripheral RH
cases after treatment; worsening of vision was
detected in other cases even when the lesion
regressed or was stable, and complications such
as macular edema and exudates were resolved.
In the latter study, it is suggested that PDT
should be recommended for RH if available, but
it is clear that therapies that are more effective
are required for difficult RH cases, including
juxtapapillary capillary hemangiomas and those
with exudative retinal detachment or macular
edema. In addition, the authors of this review have
not found PDT to be effective enough to be used
routinely.
Surgical Excision of Extrapapillary RHs
Asmentioned before, there are significant risks and
low success rates of ablation in very large RHs.
Because of that, surgical excision of RHs during vit-
rectomy is sometimes employed. In addition, vitreo-
retinal intervention is frequently essential for larger
RHs complicated by rhegmatogenous or tractional
retinal detachment.[41] In a retrospective case series
of three patients,[96] tumors 7 mm to 9 mm in
diameter were removed via internal en bloc surgi-
cal resection using a bimanual technique. Accord-
ing to patients’ favorable outcomes, the authors
suggested that surgical resection is a choice for
those with large RHs. Gaudric and colleagues
reported a case series of 23 eyes that underwent
vitreoretinal surgery for progressive ocular VHL
disease, in which 14 eyes received cryotherapy or
laser endophotocoagulation as adjunct to vitrec-
tomy and the other 9 eyes had surgical removal of
RHs.[86] For the nine eyes undergoing RH excision,
a mean of two operations was needed, and eight
out of nine eyes had an attached retina six months
following the surgery. However, NVG and new
tumor development occurred in four eyes between
four and eight years after the RH excision, and
visual acuity in remaining eyes was poor (20/320
or worse). The authors of the study claimed that
vitreoretinal surgery is an effective treatment for
severe VHL retinal hemangiomas, as in most cases,
surgery enhanced or extended visual function.
However, we believe that the combination of high
rate of RH recurrence and post-surgery proliferative
vitreoretinopathy restricts the accomplishment of
this approach.
New Concepts in Ocular VHL Disease Treat-
ment
Anti-VEGF therapy
Observation of the extremely vascularized nature
of lesions in VHL disease led to a hypothesis that
VEGF, a HIF-inducible protein and potent mediator
of angiogenesis and vascular permeability, might
be central in RHs progression, and there are numer-
ous lines of evidence fingering VEGF expression
in the pathogenesis of VHL disease. VEGF protein
levels are raised in specimens from renal carcino-
mas demonstrating mutations of VHL.[97–99]
Anti-VEGFs decrease the amount of intraretinal
edema and bleed, thereby reducing the size of
the lesion and the nourishing vessels. Anti-VEGFs
have been displayed to accelerate the clearance
of hemorrhages and exudation, which leads to the
improvement of visual acuity along with diminished
probabilities of re-bleeding.[100] In a retrospective
interventional case series,[101] it was shown that
intravitreal anti-VEGF agents, unaided or in combi-
nationwith other treatmentmodalities, may recover
visual acuity, but additional trials assessing the
dose, the quantity of injections, and the route
of administration will be essential in evolving
antiangiogenic therapies for RH. Earlier, in one
prospective study, Dahr and coworkers assessed
intravitreous pegaptanib sodium (3 mg) in five
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patients manifesting juxtapapillary or extrapapillary
RH.[102] Pegaptanib sodiumwas administered every
six weeks for at least six injections, and two of
five patients finished the course and one year
of follow-up. These two patients experienced a
reduction in exudation, but no alteration in dimen-
sions of the tumors. The other three patients
demonstrated advancement of ocular disease and
did not finish the course of treatment. In another
interventional case series, Wong et al evaluated
the effect of intravitreal ranibizumab in five patients
with retinal hemangiomas not responsive to stan-
dard treatments.[103] Ranibizumab (0.5 mg) was
administrated every one month for six months,
with supplementary treatment through 12 months.
Participants received an average of 10 injections
over a mean of 47 weeks. Visual acuity declined by
nine letters and there was no consistent reduction
in RH tumor size or improvement in exudation.
Recently, Agarwal et al[100] reported a case with
RH located in the perifoveal region treated with
two monthly intravitreal injections of bevacizumab
followed by laser photocoagulation of feeder arte-
rioles. This combination therapy resulted in a reso-
lution of exudation, bleeding, and macular edema
with improvement in visual acuity.
Intravitreal Propranolol
The therapeutic effect of intravitreal propranolol
on retinal capillary hemangioma was reported in
a patient with VHL. No short-term adverse effects
except a mild transient inflammatory response
were observed in this case report.[104] Fluorescein
leakage was decreased from the RHs located
on the optic nerve head and in the inferonasal
retinal periphery one month after the second
intravitreal injection of propranolol. Decrease of
the hemangioma vascularity and augmentation of
its fibrosis associated with the attenuation of the
feeder vessel were observed. Electroretinogram
done one month after the first injection revealed
no retinal toxicity.
Treatment of Juxtapapillary RHs
Reduction of visual acuity, visual field loss, and
development of central scotomas have limited
the ablative therapies in managing juxtapapil-
lary hemangiomas. According to findings of mul-
tiple studies mentioned earlier, reduced visual
function has been associated with thermal laser
photocoagulation.[105] On the other hand, PDT with
verteporfin, which seems to have a safer profile
than laser photocoagulation, has demonstrated
incomplete success and fairly varied results.[82, 106]
In a retrospective case series in 2000,[105] it was
claimed that close follow-up and multiple treat-
ments with argon laser are probably the best
therapeutic approach, as if left untreated, papil-
lary angiomatous lesions may evolve to exuda-
tive retinal detachment with severe visual acuity
decreases. Given these considerations, asymp-
tomatic juxtapapillary RHs are usually observed
with the hope that some lesions remain relatively
static for long periods. It is believed that exudation
maywax andwane and can remain compatible with
good vision unless the central macula becomes
chronically affected. In the absence of safe ablative
choices, treatment is typically limited to alleviat-
ing the exudation affecting vision. Pharmacother-
apy using corticosteroids or VEGF antagonists,
proton beam therapy, and PDT may decrease
exudation in some patients, but risks of therapy
must be carefully evaluated, and success is often
limited.[91, 102, 103]
Treatment of Retinal Vascular Proliferation
As mentioned earlier in the clinical manifesta-
tions section, a series of VHL patients have
been described with an infrequent retinal pro-
liferation varying in natural history, phenotype,
and treatment.[54] They do not appear to carry
the equal risk of vitreous hemorrhage or trac-
tion retinal detachment as neovascularization in
other ischemic retinopathies, and they sometimes
regress spontaneously. When they grow large to
be more contractile due to fibrosis adjacent to the
fovea, they can reduce visual acuity. It is essential
to distinguish these lesions from RHs. Retinal
vascular proliferation does not typically cause exu-
dation and does not regress easily in response to
laser photocoagulation, in part due to its epiretinal
situation. In cases of recognized progression, these
lesions may be effectively addressed by excision
with vitrectomy and membrane peeling.[54]
SUMMARY
RH is a benign vascular tumor of the neurosensory
retina or optic disc that sometimes appears as a
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sporadic lesion, but classically manifests as one
or more tumors in the setting of VHL disease.
Referral of a patient with RH for clinical and genetic
testing for VHL disease may be lifesaving, given
the deadly nature of manifestations such as CNS
hemangioblastoma and RCC, and given the profits
of surveillance and early treatment in affected
individuals. Other essential constituents of ophthal-
mologic management include suitable surveillance
of patients with VHL disease for growth or devel-
opment of RHs and retinal vascular proliferation.
RHs developing in proximity to the optic disc exhibit
a specific challenge, because they are normally
not safe to abolish using traditional ablative pro-
cedures. Improved knowledge of the molecular
pathology of VHL disease presents possibility for
development of non-ablative therapies to stop
growth or accelerate the regression of RH in this
condition.
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